AXIA Q2 2026 Call Reinforces Wait-and-See Stance Amid Asset Sale Execution

What happened

AXIA’s Q2 2026 earnings call confirmed operational stability in transmission and generation but provided no major new catalysts, leaving the investment case centered on pending asset sales. Management reiterated progress on the CADE-approved GEBBRAS transmission stake sale and ongoing work to satisfy Eletronuclear divestment conditions, though neither has closed. The Novo Mercado migration is complete and ADR delisting is proceeding, yet the stock remains range-bound near $10.60 as the market waits for cash proceeds to materialize. Leverage metrics remain stressed with net debt/EBITDA at 16.8x and interest coverage at 2.3x, keeping financing risk elevated despite current covenant compliance. The call reinforced that tangible execution of asset rotation is the critical path to self-funded capex and credit improvement.

Implication

The Q2 update underscores that AXIA’s equity value remains tightly linked to the timing of asset sale proceeds, with no new information to alter the wait-and-see thesis. With no imminent catalysts, the stock is likely to remain range-bound until closings are announced, and any slippage could pressure funding costs given the heavy capex schedule. Investors should watch for the GEBBRAS cash receipt by September 30 and the Eletronuclear guarantee release by year-end as the next concrete signals. Until net debt/EBITDA trends sustainably below 6x, the margin of safety is thin, and the current price already discounts successful execution. We maintain a WAIT rating with an attractive entry near $9.50 and a trim target at $13.50.

Thesis delta

The Q2 call did not introduce material new facts; the thesis that AXIA’s risk-reward is balanced with upside contingent on asset sale cash proceeds and downside from leverage and regulatory volatility remains intact. No change to the WAIT rating or the $11.50 base-case implied value.